Ultralife Corporation (NASDAQ:ULBI - Get Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.62 and traded as high as $9.01. Ultralife shares last traded at $8.75, with a volume of 34,454 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded shares of Ultralife from a "buy" rating to a "strong-buy" rating in a research note on Friday, June 6th.
Check Out Our Latest Research Report on ULBI
Ultralife Price Performance
The stock has a market capitalization of $143.35 million, a PE ratio of 26.94 and a beta of 1.00. The business has a fifty day moving average price of $7.79 and a 200-day moving average price of $6.62. The company has a current ratio of 3.22, a quick ratio of 1.70 and a debt-to-equity ratio of 0.37.
Ultralife (NASDAQ:ULBI - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.02). The business had revenue of $50.75 million for the quarter, compared to analysts' expectations of $54.50 million. Ultralife had a net margin of 3.05% and a return on equity of 4.61%. During the same quarter in the previous year, the company earned $0.21 earnings per share.
Insider Transactions at Ultralife
In other Ultralife news, Director Thomas Louis Saeli purchased 5,000 shares of Ultralife stock in a transaction that occurred on Wednesday, May 14th. The shares were bought at an average price of $5.44 per share, for a total transaction of $27,200.00. Following the acquisition, the director directly owned 85,000 shares in the company, valued at approximately $462,400. This trade represents a 6.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bradford T. Whitmore bought 11,980 shares of Ultralife stock in a transaction dated Friday, May 23rd. The shares were acquired at an average cost of $5.41 per share, for a total transaction of $64,811.80. Following the completion of the purchase, the director directly owned 1,060,067 shares of the company's stock, valued at approximately $5,734,962.47. This trade represents a 1.14% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 47,140 shares of company stock valued at $256,355. 40.00% of the stock is currently owned by company insiders.
Institutional Trading of Ultralife
Several large investors have recently bought and sold shares of the company. IFP Advisors Inc boosted its position in shares of Ultralife by 24.6% during the first quarter. IFP Advisors Inc now owns 14,200 shares of the technology company's stock valued at $76,000 after purchasing an additional 2,800 shares in the last quarter. Jones Financial Companies Lllp lifted its position in Ultralife by 1,428.7% during the first quarter. Jones Financial Companies Lllp now owns 15,287 shares of the technology company's stock valued at $82,000 after buying an additional 14,287 shares during the period. Bank of America Corp DE boosted its holdings in shares of Ultralife by 30.7% during the 4th quarter. Bank of America Corp DE now owns 12,067 shares of the technology company's stock valued at $90,000 after buying an additional 2,836 shares in the last quarter. Barclays PLC grew its position in shares of Ultralife by 13.7% in the 4th quarter. Barclays PLC now owns 15,233 shares of the technology company's stock worth $113,000 after buying an additional 1,838 shares during the period. Finally, Pitti Group Wealth Management LLC grew its position in shares of Ultralife by 23.4% in the 1st quarter. Pitti Group Wealth Management LLC now owns 21,120 shares of the technology company's stock worth $114,000 after buying an additional 4,000 shares during the period. 30.68% of the stock is owned by institutional investors.
About Ultralife
(
Get Free Report)
Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.
Further Reading
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
